Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar;14(2):599-605.
doi: 10.1111/cts.12917. Epub 2020 Nov 24.

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

K Chris Min  1 , Walter K Kraft  2 , Phung Bondiskey  3 , Francheska Colón-González  3 , Wen Liu  3 , Jialin Xu  1 , Deborah Panebianco  3 , Lori Mixson  1 , Marissa F Dockendorf  3 , Catherine Z Matthews  3 , Ramesh Boinpally  4
Affiliations
Clinical Trial

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

K Chris Min et al. Clin Transl Sci. 2021 Mar.

Abstract

Atogepant is a potent, selective, oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical structure of atogepant is distinct from previous CGRP receptor antagonists, which were associated with elevated serum alanine aminotransferase (ALT) in clinical trials. Here, we report the safety, tolerability, and pharmacokinetics (PKs) of a once-daily supratherapeutic dose (170 mg) of atogepant for 28 days from a randomized, double-blind, placebo-controlled phase I trial in healthy participants. Overall safety, hepatic safety, and plasma PK parameters were evaluated. Thirty-four participants aged 23-55 years enrolled; 28 (82.4%) completed the study in accordance with the protocol. Multiple doses of 170 mg atogepant for 28 consecutive days were generally well-tolerated. All adverse events (AEs; reported in 87.0% of the atogepant group; 72.7%, placebo) were mild in severity except one serious AE of subarachnoid hemorrhage due to a bicycle accident and not considered related to treatment. There were two discontinuations due to AEs, both with atogepant, one considered possibly related to treatment. Over 28 days of treatment, no participant receiving atogepant had an ALT elevation above 1.5 × upper limit of normal. Change from baseline in serum ALT levels was not different between atogepant and placebo. Atogepant is rapidly absorbed (median time to maximum plasma concentration, ~ 2 hours) with an apparent terminal half-life of ~ 11 hours, and no evidence of accumulation after once-daily dosing. Overall, atogepant at a high oral dose is safe and well-tolerated in healthy participants with no clinically meaningful elevations in ALT.

Trial registration: ClinicalTrials.gov NCT03700320 NCT03777059 NCT03855137 NCT03939312.

PubMed Disclaimer

Conflict of interest statement

K.C.M., J.X., and L.M. were employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, with stock in Merck & Co., Inc., Kenilworth, NJ, USA, at the time of this study. W.K.K. served as a consultant to Merck in 2019 for a topic unrelated to atogepant. P.B., F.C.‐G., W.L., D.P., M.F.D., and C.Z.M. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, with stock in Merck & Co., Inc., Kenilworth, NJ, USA. R.B. is an employee of AbbVie, and may hold AbbVie stock.

Figures

Figure 1
Figure 1
Participant disposition.
Figure 2
Figure 2
Atogepant concentrations in plasma over time. Arithmetic mean values for atogepant plasma concentration over time following administration of 170 mg q.d. for 28 days in fasted healthy participants are shown on (a) linear scale and (b) log‐linear scale. Error bars represent SDs.
Figure 3
Figure 3
Serum ALT concentrations over time. Arithmetic mean values for ALT serum concentration at baseline and following administration of atogepant 170 mg q.d. (black line) or placebo q.d. (gray line) for 28 days in healthy participants. Dotted and dashed lines indicate ALT ULN for men (45 IU/L) and women (30 IU/L), respectively. ALT, alanine aminotransferase; ULN, upper limit of normal.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pietrobon, D. & Moskowitz, M.A. Pathophysiology of migraine. Annu. Rev. Physiol. 75, 365–391 (2013). - PubMed
    1. Burch, R.C. , Buse, D.C. & Lipton, R.B. Migraine: epidemiology, burden, and comorbidity. Neurol. Clin. 37, 631–649 (2019). - PubMed
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211–1259 (2017). - PMC - PubMed
    1. Steiner, T.J. , Stovner, L.J. , Vos, T. , Jensen, R. & Katsarava, Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J. Headache Pain 19, 17 (2018). - PMC - PubMed
    1. Lipton, R.B. , Bigal, M.E. , Diamond, M. , Freitag, F. , Reed, M.L. & Stewart, W.F. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68, 343–349 (2007). - PubMed

Publication types

MeSH terms

Associated data